<DOC>
	<DOCNO>NCT02460263</DOCNO>
	<brief_summary>The purpose study evaluate Tablo Hemodialysis System use In-Center trained individual In-Home train Subjects .</brief_summary>
	<brief_title>The EvAluation TaBlo In-CLinic In-HOme</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Subject end stage renal disease ( ESRD ) adequately treated maintenance dialysis achieve Kt/V â‰¥ 1.2 deem stable least three month his/her treat nephrologist . Subject wellfunctioning stable vascular access allow blood flow least 300 ml/min . Life expectancy le 12 month first study procedure . Subject recent major cardiovascular adverse event within last 3 month . Subject New York Class III IV Congestive Heart Failure , ejection fraction le 30 % . Subject fluid overload due intractable ascites secondary liver cirrhosis . Subject uncontrolled blood pressure . Subject intolerant heparin . Subject seroreactive Hepatitis B Surface Antigen . Subject active , lifethreatening , rheumatologic disease . Subject history adverse reaction dialyzer membrane material . Subject expect receive organ transplant course study . Subject lifethreatening malignancy actively receive treatment would prevent successful completion study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>